Table 2.
Efficacy of Genetic testing regimen for minor stroke and acute TIA patients.
| Model input | Genetic testing | Non-genetic testing | References | ||
|---|---|---|---|---|---|
| Proportion of patients after 90 days | 19,32 | ||||
| Minor or no disability (mRS 0–2) | 0.9506 | 0.9376 | |||
| Moderate disability (mRS 3–4) | 0.0404 | 0.0527 | |||
| Severe disability (mRS 5) | 0.0054 | 0.0058 | |||
| Death (mRS 6) | 0.0036 | 0.0039 | |||
| 90-day event risks | CYP2C19 LoFA non-carriers* | CYP2C19 LoFA carriers† and ESRS ≥ 3 | CYP2C19 LoFA carriers and ESRS < 3 | 19,21,32 | |
| Recurrent stroke | 0.0717 | 0.0871 | 0.0727 | 0.082 | |
| Proportion of ICH | 0.0377 | 0.0377 | 0.0377 | 0.0377 | |
| Major ECH | 0.0108 | 0.0108 | 0.0108 | 0.0108 | |
| MI | 0.0012 | 0.0012 | 0.0012 | 0.0012 |
Minor stroke minor stroke, TIA transient ischemic attack, mRS modified Rankin Score, ICH intracerebral hemorrhage, ECH extracranial hemorrhage, MI myocardial infarction.
*CYP2C19 LoFA non-carriers were defined as patients without LoFA of *2 and *3 (*1/*1, *1/*17, or *17/*17).
†CYP2C19 LoFA carriers were defined as patients with at least one LoFA of *2 or *3 (*1/*2, *1/*3, *2/*2, *2/*3, *3/*3, *2/*17, or *3/*17).